Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00264
|
|||||
Drug Name |
Verapamil
|
|||||
Synonyms |
(+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Arpamyl; Bosoptin (TN); CP-16533-1; Calan; Calan (TN); Calcan; Cordilox; Covera-HS (TN); D-365; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isoptin (TN); Isotopin; Vasolan; Veracim; Verapamil (Na-Ca chanel blocker); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Verapamilo; Verapamilo [INN-Spanish]; Verapamilum; Verapamilum [INN-Latin]; Veraptin; Verelan (TN); Verexamil
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Angina [ICD11: BA40] | Approved | [1] | |||
High blood pressure [ICD11: BA00] | Approved | [1] | ||||
Therapeutic Class |
Analgesics
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C27H38N2O4
|
|||||
Canonical SMILES |
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
|
|||||
InChI |
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
|
|||||
InChIKey |
SGTNSNPWRIOYBX-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 52-53-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 454.6 | Topological Polar Surface Area | 64 | ||
Heavy Atom Count | 33 | Rotatable Bond Count | 13 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
3.8
|
|||||
PubChem CID | ||||||
PubChem SID |
10525256
, 11120305
, 11120793
, 11121281
, 11121578
, 11122058
, 11335574
, 11360813
, 11362647
, 11364755
, 11365209
, 11367317
, 11367771
, 11369879
, 11370565
, 11370566
, 11372920
, 11373372
, 11374511
, 11375479
, 11375933
, 11378044
, 11424501
, 11461785
, 11466169
, 11467289
, 11485556
, 11485917
, 11489556
, 11492721
, 14784349
, 26751824
, 26751825
, 29221683
, 3153219
, 46508158
, 47217025
, 47291346
, 47291347
, 47440510
, 47515567
, 47589211
, 47885631
, 48035377
, 5635244
, 598709
, 7849415
, 7980877
, 8151673
, 9397
|
|||||
ChEBI ID |
ChEBI:9948
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MDR3 | Transporter Info | Multidrug resistance protein 3 | Substrate | [2] | |
MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [4] | ||
OCTN1 | Transporter Info | Organic cation/carnitine transporter 1 | Substrate | [5] | ||
OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [6] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [7] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | P-GP | Transporter Info | Km = 4.06 microM | High five cells-MDR1 | [8] | |
P-GP | Transporter Info | Km = 24 microM | Madin-Darby canine kidney cells (MDCKII)-MDR1 | [9] | ||
P-GP | Transporter Info | Km = 2 microM | Spodoptera frugiperda (Sf9) cells-MDR1 | [10] | ||
P-GP | Transporter Info | Km = 4.1 microM | Spodoptera frugiperda (Sf9) cells-MDR1 | [11] | ||
References | ||||||
1 | Verapamil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9. | |||||
3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
4 | Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. | |||||
5 | Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. | |||||
6 | Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9. | |||||
7 | Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14. | |||||
8 | Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. | |||||
9 | Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein (P-gp/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1). J Med Chem. 2012 May 24;55(10):4683-99. | |||||
10 | Synthesis and evaluation of 3D templates based on a taxane skeleton to circumvent P-glycoprotein-associated multidrug resistance of cancer. Bioorg Med Chem Lett. 2005 May 16;15(10):2601-5. | |||||
11 | Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.